WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device
company focused on the treatment and management of the neurological
complications of diabetes, has been featured in several media outlets
that spotlighted the Company and the SENSUS™ Pain Management
System. SENSUS is a convenient and wearable non-invasive electrical
nerve stimulator that offers patients a fast-acting, non-narcotic option
for relief from chronic pain. The device is lightweight and can be worn
during the day while remaining active, or at night while sleeping. It is
optimally designed for people with diabetes that suffer from chronic
pain. The most common cause of such pain is painful diabetic neuropathy
(PDN), which affects up to five million people in the U.S. alone.
NeuroMetrix is referenced in the article "What ‘Smart Fabrics' Mean for
the Future of Health" on Healthline.com, a
consumer-focused health site. The article highlights SENSUS as part of
the growing trend of wearable technology. Shai Gozani, M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix is quoted: "The
notion of smart wearable technology is expanding...It's exciting for
people who have health needs because it makes delivering therapy easier
and more successful for patients...That's the ultimate desired outcome."
To read the article, please visit the following link: http://www.healthline.com/health-news/tech-smart-fabrics-future-of-health-011614
Dr. Gozani was interviewed on Allie's Voice, an
influential diabetes blog focusing on medical advancements and research
to improve the quality of life for people with diabetes. To read the
interview, please visit the following link: http://www.alliesvoice.com/2014/01/17/sensus-pain-management-system/
Dr. Gozani was also interviewed on Your Family's Health on
90.3 FM, a radio show based in the Long Island, New York area. During
the program, Dr. Gozani provided an overview of peripheral neuropathy
and its effect on cost, lifestyle and health. The second half of the
show focused on SENSUS as an attractive therapy option for patients with
painful neuropathy. To listen to the interview in its entirety, please
visit the following link: http://www.sensusrx.com/about-neurometrix/news-and-events/your_family's_healtlh__peripheral_neuropathy._dr_shai_gozani_nmp3.mp3
A recent article in MedCity
News titled "Wearable diabetic neuropathy pain
management system strives for simplicity" provides an overview of SENSUS
and highlights the device's simple design. Dr. Gozani is quoted: "We
wanted to make this as easy to use as taking a pill. Because really
that's the alternative in a sense-a pain pill. . . . The last thing they
need is another complicated device to try to manage everything else
going on in their lives." To read the article, please visit the
following link: http://medcitynews.com/2013/11/wearable-diabetic-neuropathy-treatment-pain-management-strives-one-button-simplicity/#
Lastly, Diabetes Self-Management listed SENSUS as one of the
"Tools of the Trade 2013." Diabetes Self Management is a
publisher of authoritative, reliable health information for the growing
number of people with diabetes who want to know more about controlling
and managing their diabetes. To read the article, please visit the
following link: http://medcitynews.com/2013/11/dave-eggers-circle-future-of-healthcare-big-data-digital-health/
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for
treating chronic pain, focusing on physicians managing patients with
painful diabetic neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit http://www.neurometrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
